Genzyme/Third Wave
This article was originally published in The Gray Sheet
Executive Summary
Firms form preferred marketing relationship for Third Wave's Invader UGT1A1 molecular assay, which assesses the potential of adverse reactions to the chemotherapy drug Camptosar (Pfizer) for colorectal cancer. The test was 510(k)-cleared in August (1"The Gray Sheet" Aug. 29, 2005, p. 26). Genzyme announced exclusive diagnostic rights to the UCLA Jonsson Cancer Center's discovery of gene mutations associated with drug resistance to Novartis' Gleevec, used to treat chronic myeloid leukemia, Oct. 6...
You may also be interested in...
FDA Clears Third Wave Invader Pharmacogenetic Test
Oncologists will be able to use Third Wave Technologies' Invader UGT1A1 molecular assay to select appropriate doses of Pfizer's chemotherapy drug Camptosar (irinotecan)for colorectal cancer, following 510(k) clearance Aug. 22
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.